Prime Medicine shares rose after the company said the first patient has been dosed in a Phase 1/2 clinical trial of PM577a, an investigational in vivo prime editor for H1069Q-mutated Wilson disease.
The stock was 21% higher, at $5.27, on Wednesday, just off its 52-week high earlier in the session.
The biotechnology company said the milestone marks the first clinical evaluation of its liver franchise.
The company also announced that the Food and Drug Administration has granted rare pediatric disease designation to PM577 for Wilson disease.
The Phase 1/2 clinical trial is an open-label, global, first-in-human study designed to evaluate the safety, tolerability and preliminary clinical efficacy of ascending doses of PM577a in adults and adolescents with Wilson disease containing at least one p.H1069Q allele in the ATP7B gene.
The company said the study will initially enroll adults who are clinically stable on standard-of-care therapy.
Comments